Molecular understanding of hyperglycemia's adverse effects for diabetic complications

JAMA

Volumn 288, Issue 20, 2002, Pages 2579-2588

  Sheetz, Matthew J ^a   King, George L ^b,c  

^a ELI LILLY AND COMPANY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; DIACYLGLYCEROL; GLUCOSE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

ARTICLE; CATARACT; CLINICAL PATHWAY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPEROSMOLALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0037184495     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.20.2579     Document Type: Article

References (154)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. Klein R, Klein BEK, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: A review. Diabetes Metab Rev. 1989;5:559-570.
4. Klein R, Klein BEK. Vision disorders in diabetes. In: Hamman R, Harris MWH, eds. Diabetes in America. Bethesda, Md: National Institutes of Health; 1982. US Public Health Service/NIH Publication 85-1468, vol 13:1-36.
5. Bursell SE, Clermont AC, Kinsley BT, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37:886-897.
6. Kohner EM, Patel V, Rassam SMB. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes. 1995;44:603-607.
7. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary non-perfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81-100.
8. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2638-2651.
9. Aiello LP, Cavallerano J, Bursell SE. Diabetic eye disease. Endocrinol Metab Clin North Am. 1996;25:271-291.
10. Miller JW, Adamis AP, Aiello LP, Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
11. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol. 2000;184:301-310.
12. Shinoda K, Ishida S, Kawashima S, et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol. 1999;83:834-837.
13. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
14. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science. 1999;285:245-248.
15. Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol. 2001;132:378-382.
16. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98:766-785.
17. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurology. 1993;43:817-824.
18. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans. J Neuropathol Exp Neurol. 1996;55:1181-1193.
19. Sima AAF, Thomas PK, Ishii D, Vinik A, Diabetic neuropathies. Diabetologia. 1997;40(suppl 3):B74-B77.
20. Boulton AJM. Foot problems in patients with diabetes mellitus. In: Pickup J, Williams G, eds. Textbook of Diabetes. London, England: Blackwell Science; 1997:1-58.
21. Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetoiogia. 1993;36:454-459.
22. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans. J Neuropathol Exp Neurol. 1996;55:1181-1193.
23. Sugimoto K, Murakawa Y, Sima AAF Diabetic neuropathy - A continuing enigma. Diabetes Metab Res Rev. 2000;16:408-433.
24. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973-1988.
25. Greene DA, Sima AAF, Stevens MJ, et al. Complications: Neuropathy, pathogenetic considerations. Diabetes Care. 1992;15:1902-1925.
26. Srinivasan S, Stevens M, Wiley JW. Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction. Diabetes. 2000;49:1932-1938.
27. Griffey RH, Eaton RP, Sibbitt RR, et al. Diabetic neuropathy: Structural analysis of nerve hydration by magnetic resonance spectroscopy. JAMA. 1988;260:2872-2878.
28. Dyck PJ, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci U S A. 1985;82:2513-2517.
29. Myers RR, Powell HC. Galactose neuropathy: Impact of chronic endoneurial edema on nerve blood flow. Ann Neurol. 1984;16:587-594.
30. Samii A, Unger J, Lange W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett. 1999;262:159-162.
31. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest. 2001;107:1083-1092.
32. Kihara M, Low PA. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol. 1995;132:180-185.
33. Maxfield EK, Cameron NE, Cotter MA. Effects of diabetes on reactivity of sciatic vasa nervorum in rats. J Diabetes Complications. 1997;11:47-55.
34. Hopfner RL, Gopalakrishnan V. Endothelin: Emerging role in diabetic vascular complications. Diabetologia. 1999;42:1383-1394.
35. Low PA, Tuck RR, Dyck PJ, et al. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci U S A. 1984;81:6894-6898.
36. Cameron NE, Cotter MA. Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats. J Pharmacol Exp Ther. 1996;278:1262-1268.
37. Tesfaye S, Malik R, Ward JD, Vascular factors in diabetic neuropathy. Diabetologia. 1994;37:847-854.
38. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127-1133.
39. Craven PA, Caines MA, DeRubertis FR. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats. Metabolism. 1987;36:95-103.
40. Perico N, Benignim A, Gabanelli M, et al. Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperfusion of diabetic rats. Diabetes. 1992;41:533-538.
41. Sharma K, Danoff TM, DePiero A, Ziyadeh FN. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels. Biochem Biophys Res Commun. 1995;207:80-88.
42. Schleicher E, Kolm V, Ceol M, Nerlich A. Structural and functional changes in diabetic glomerulopathy. Kidney Blood Press Res. 1996;19:305-315.
43. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229-2239.
44. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632.
45. Min W, Yamanak N. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy, Virchows Arch A Pathol Anat Histopathol. 1993;423:201-207.
46. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis. 1993;22:736-744.
47. Osterby R, Parving HH, Nyberg G, et al. A strong correlation between glomerular filtration rate and surface in diabetic nephropathy. Diabetologia. 1988;31:265-270.
48. Iwano M, Kubo A, Nishino T, et al. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int. 1996;49:1120-1126.
49. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 2000;58:1389-1399.
50. Bollineni JS, Reddi AS. Transforming growth factor-β1 enhances glomerular collagen synthesis in diabetic rats. Diabetes. 1993;42:1673-1677.
51. Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int. 1993;43:109-113.
52. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. Clin Invest. 1994;93:536-542.
53. Buschhausen L, Seibold S, Gross O, et al. Regulation of mesangial cell function by vasodilatory signaling molecules. Cardiovasc Res. 2001;51:463-469
54. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents. Nephrol Dial Transplant. 1995;10:1963-1974.
55. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
56. Shepro D, Morel NML. Pericyte physiology. FASEB J. 1993;7:1031-1038.
57. Rippin JD, Patel A, Bain SC. Genetics of diabetic nephropathy. Best Pract Res Clin Endocrinol Metab. 2001;15:345-358.
58. Evans K, Bird AC. The genetics of complex ophthalmic disorders. Br J Ophthalmol. 1996;80:763-768.
59. Kinoshita JH. Mechanisms initiating cataract formation: Proctor lecture. Invest Ophthalmol. 1974;13:713-724.
60. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med. 1975;26:521-536.
61. Van den Enden MK, Nyengaard JR, Ostrow E, et al. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Invest Ophthalmol Vis Sci. 1995;36:1675-1685.
62. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med. 1994;16:383-391.
63. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801-813.
64. Robison WG Jr, Nagata M, Laver N, et al. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci. 1989;30:2285-2292.
65. Kador PF, Akagi Y, Takahashi Y, et al. Prevention of retinal vessel changes associated with diabetic retinoathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1990;108:1301-1309.
66. Mauer SM, Steffes MW, Azar S, Brown DM. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes. 1989;38:839-846.
67. Yue DK, Hanwell MA, Satchell PM, Turtle JR. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes. 1982;31:789-794.
68. Cameron NE, Leonard MB, Ross IS, Whiting PH. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia. 1986;29:168-174.
69. Sorbinil Retinopathy Trial Research Group. A randomized trial of Sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol. 1990;108:1234-1244.
70. Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Biomed Pharmacother. 1995;49:269-277.
71. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care. 2001;24:1776-1782.
72. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Nati Acad Sci U S A. 1984;81:583-587.
73. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984;101:527-537.
74. Brownlee M. Advanced protein glycosylation in diabetes and aging Annu Rev Med. 1995;46:223-234.
75. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J Clin Invest. 1994;94:110-117.
76. Chibber R, Molinatti PA, Kohner EM. Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. Cell Mol Biol (Noisy-le-grand). 1999;45:47-57.
77. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab. 2000;11:368-375.
78. el Khoury J, Thomas CA, Loike JD, et al. Macrophages adhere to glucose-modified basement membrane via their scavenger receptors. J Biol Chem. 1994;269:10197-10200.
79. Vlassara H, Li YM, Imani F, et al. Galectin-2 as a high affinity binding protein for AGE. Mol Med 1995;1:634-646.
80. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232:1629-1632.
81. Friedman E. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care. 1999;22(suppl 2): B65-B71.
82. Nilsson BO. Biological effects of aminoguanidine. Inflamm Res. 1999;48:509-515.
83. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. J Clin Invest. 1996;97:238-243.
84. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
85. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Biochem J. 1988;256:205-212.
86. Suzuki S, Hinokio Y, Komatu K, et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res Clin Pract. 1999;45:161-168.
87. Tesfamariam B. Selective impairment of endothelium-dependent relaxation by prostaglandin endoperoxides. J Hypertens. 1994;12:41-47.
88. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257-267.
89. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412
90. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol. 2001;280:C719-C741.
91. Craven PA, Melhem MF, Phillips SL, DeRubertis FR. Overexpression of Cu/Zn superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes. 2001;50:2114-2125.
92. Jain SK, McVie R. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism. 1994;43:306-309.
93. Jennings PE, Chirico S, Jones AF, et al. Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res. 1987;6:151-154.
94. Karpen CW, Cataland S, D'Orisio TM, Panganamala RV. Production of 12 HETE and vitamin E status in platelets from type 1 human diabetic subjects. Diabetes. 1985;34:526-531.
95. Obedey LW. Free radicals and diabetes. Free Radic Biol Med. 1988;5:113-124.
96. Hayden JM, Reaven PD. Cardiovascular disease in diabetes mellitus type 2. Curr Opin Lipidol. 2000;11:519-528.
97. Devaraj S, Hirany SV, Burk RF, Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem. 2001;47:1974-1979.
98. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. J Clin Invest. 1995;96:1159-1163.
99. Cameron NE, Cotter MA, Archibald V, et al. Antioxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia. 1994;37:449-459.
100. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995;18:1160-1167.
101. Lal MA, Korner A, Matsuo Y, et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes. 2000;49:1381-1389.
102. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. Diabetes. 2001;50:1938-1942.
103. Bursell SE, Clermont AC, Aiello LP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care. 1999;22:1245-1251.
104. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
105. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607-614.
106. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats. Proc Natl Acad Sci U S A 1992;89:11059-11063.
107. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med. 1998;76:21-31.
108. Nagpala PG, Malik AB, Vuong PT, Lum H. Protein kinase C β1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol. 1996;166:249-255.
109. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. Circulation. 2000;101:676-681.
110. Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betall PKC activation. Am J Physiol Heart Circ Physiol. 2001;280:H621-H627.
111. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-β inhibitor (Ruboxistaurin mesylate) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000;41:2702-2706.
112. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-E793.
113. Williams B, Gallagher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes. 1997;46:1497-1503.
114. Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase β-isoform activation on the gene expression of transforming growth factor β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100:115-126.
115. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
116. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol. 1998;32(suppl 3): S2-S13.
117. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia. 1999;42:1271-1281.
118. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J. 1998;332:281-292.
119. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-E793.
120. Babazono T, Kapor-Drezgic J, Dlugosz JA, Whiteside C. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. Diabetes. 1998;47:668-676.
121. Meier M, King GL. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med. 2000;5:173-185.
122. Ishii H, Jirousek, MR, Koya D, et al. Ameliouration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science. 1996;272:728-731.
123. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
124. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthatmol Vis Sci. 1998;39:171-179.
125. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes. 1999;48:2090-2095.
126. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14:439-447.
127. Hamada Y, Araki N, Koh N, et al. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Comm. 1996;228:539-543.
128. Wells-Knecht KJ, Zyzak DV, Litchfield LE, et al. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry. 1995;34:3702-3709.
129. Wells-Knecht MC, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry. 1995;34:15134-15141.
130. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/ binding proteins. J Biol Chem. 1994;269:9889-9897.
131. Hothersall JS, Muirhead RP, Taylaur CE, Jones RH. Anti-oxidant status in an in vitro model for hyperglycaemic lens cataract formation. Biochem Int. 1992;27:945-952.
132. Bravi MC, Pietrangeli P, Laurenti O, et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism. 1997;46:1194-1198.
133. Asahina T, Kashiwagi A, Nishio Y, et al. Impaired activation of glucose oxidation and NADPH supply in human endothelial cells exposed to H2O2 in high-glucose medium. Diabetes. 1995;44:520-526.
134. Anderson MM, Requena JR, Crowley JR, et al. The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins. J Clin Invest. 1999;104:103-113.
135. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-1945.
136. Kim YS, Kim BC, Song CY, et al. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med. 2001;138:59-68.
137. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-17814.
138. Taher MM, Garcia JGN, Natarajan V. Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Arch Biochem Biophys. 1993;303:260-266.
139. Sundaresan M, Yu ZX, Ferrans VJ, et al. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
140. Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes J Biol Chem. 1995;270:11727-11730
141. Ha H, Lee HB. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. 2000;58(suppl 77): S19-S25. The journal name is valid, but no match was found at PubMed
142. Wang XT, McCullough KD, Wang XJ, et al. Oxidative stress-induced phospholipase C-gamma 1 activation enhances cell survival. J Biol Chem. 2001;276:28364-28371.
143. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol. 1998;9:319-324.
144. Araki S, Makita Y, Canani L, et al. Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type 1 diabetes mellitus. Diabetologia. 2000;43:1540-1543.
145. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease. Lancet. 1996;347:781-786.
146. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. Lancet. 1999;354:447-455.
147. Lee IK, Koya D, Ishi H, et al. d-Alpha-tocopherol prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes Res Clin Pract. 1999;45:183-190.
148. Studer RK, Craven PA, DeRubertis FR. Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. Metabolism. 1997;46:918-925.
149. Soriano FG, Pacher P, Mabley J, et al. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res. 2001;89:684-691.
150. Ido Y, Chang KC, Lejeune WS, et al. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation. 2001;8:251-263.
151. Ren S, Shatadal S, Shen GX. Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells. Am J Physiol Endocrinol Metab. 2000;278:E656-E662.
152. Dekker LV, Leitges M, Altschuler G, et al. Protein kinase C-beta contributes to NADPH-oxidase activation in neutrophils. Biochem J. 2000;347(pt 1):285-289.
153. Chen S, Apostolova MD, Cherian MG, Chakrobarti S. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced permeability in endothelial cells. Lab Invest. 2000;80:1311-1321.
154. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98:2018-2026.